Sigma Healthcare confirmed preliminary discussions about acquiring U.K. drugstore chain Boots, sending its shares down 5.1% in Sydney trading. The Australian pharmacy group stated it regularly reviews opportunities to create shareholder value but emphasized no deal certainty exists. This marks Sigma's push to expand beyond its domestic market.

Private-equity owner Sycamore Partners has reportedly opened talks with multiple parties regarding a potential $10 billion sale. The billionaire Weston family also appears among interested bidders, according to the Financial Times. Market reaction suggests investors remain cautious about the transaction's viability.

Boots operates over 2,000 stores across the U.K. and Ireland, making it a substantial target for international expansion. Sigma's move reflects broader consolidation trends in healthcare retail as operators seek scale amid rising costs and competitive pressures. The pharmacy sector faces margin compression from NHS funding constraints and online competition.

Any successful acquisition would represent one of Australia's largest overseas healthcare deals, reshaping competitive dynamics in both markets. Sigma must navigate complex integration challenges while justifying the premium price tag to shareholders.